Is Globus Medical Inc (GMED) a risky stock?
As of July 27, 2026, Clavix grades Globus Medical Inc (GMED) C+ for risk, a composite score of 64 out of 100 on an A+ to F scale, which puts GMED in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 27, 2026. Clavix regrades every trading day.
The five risk dimensions behind GMED's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how GMED scores on each, as of July 27, 2026.
What's moving GMED's risk right now
Company-specific signals Clavix flags behind GMED's current grade, drawn from recent news and filings as of July 27, 2026.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Globus Medical, Inc. (NY…
GMED's revenue trend in core segments and financial flexibility position it for continued growth, but margin pressure from costs and FX could weigh on near-term earnings, suppo…
Globus Medical's 43.6% one-year rally is fueled by strong growth across both business segments, rising technology adoption and a debt-free balance sheet.
Recent GMED news
The latest headlines Clavix ingested for Globus Medical Inc, newest first. These feed the news-sentiment dimension of GMED's grade.
-
Globus Medical (GMED) is gaining share in musculoskeletal solutions driven by strong implant and trauma growth, supported by a debt-free balance sheet, though it faces cost and foreign exchange headwinds.
What a C+ grade means
On the Clavix A+ to F scale, GMED's composite of 64 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell GMED or any security. Grades are risk indicators, not predictions of return. Data may be delayed.